Truvada News and Research

RSS

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences Inc. announced Thursday that it plans to partner with Mylan Inc., Ranbaxy Laboratories Ltd. and Strides Arcolab Ltd. "to promote access to high-quality, low-cost generic versions of Gilead's HIV medicine emtricitabine in developing countries," the Wall Street Journal reports.

3 Aug 2012

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan Inc. today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations.

3 Aug 2012

GlobalPost examines debate surrounding PrEP

GlobalPost's "Global Pulse" blog examines questions surrounding the use of the antiretroviral Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at high risk, as studies released and panel discussions held last week at the XIX International AIDS Conference (AIDS 2012) "raised concerns about the drug's effect on the future of the AIDS fight."

31 Jul 2012

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

The international AIDS conference in Washington has already made two points clear. There is no prospect that scientists will any time soon find the ultimate solutions to the AIDS epidemic, namely a vaccine that would prevent infection with the AIDS virus or a "cure" for people already infected with the virus.

31 Jul 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012

Merck signs two licensing agreements for investigational HIV drug candidates

Merck, known as MSD outside the United States and Canada, announced today that the company has signed two licensing agreements for investigational HIV drug candidates.

25 Jul 2012

Dapivirine Phase III trial now underway in Africa to treat HIV in women

A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women - a vaginal ring used once a month - is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).

25 Jul 2012

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

Warner C. Greene, MD, who directs virology and immunology research at the Gladstone Institutes, has joined with other global AIDS experts to release a locally affordable version of the world's leading AIDS medical textbook. Designed specifically for regions that today are hardest hit by the disease, this new text is the latest weapon in a growing arsenal aimed at curbing the spread of HIV/AIDS worldwide.

24 Jul 2012

Views on AIDS: Despite advances, still no cure, no vaccine, and indifference grows

The story of the AIDS pandemic has been grim for so long that optimism seems hardly possible. But as the 19th International AIDS conference opens in Washington on Sunday, there is hope for control of a disease that has killed nearly 35 million people over three decades and 1.7 million in the past year.

23 Jul 2012

South Africa making progress against HIV/AIDS, but still more effort needed, health minister says

Though South Africa has made progress against HIV/AIDS over the past few years, the country's "health minister says much more needs to be done," VOA News reports.

21 Jul 2012

UNMC's ART injectables can successfully treat HIV infection

This has been a good week for breakthroughs in HIV/AIDS. Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team's progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be highlighted as the cover story in the Journal of Infectious Diseases.

19 Jul 2012

NPR reports on Brazilian clinical trial of Truvada as prevention strategy

NPR's "Shots" blog reports on one of the drug trials considered by the FDA in its approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, which "was done at the Oswaldo Cruz Foundation Research Institute, also known as Fiocruz, in Rio de Janeiro."

19 Jul 2012

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection.

19 Jul 2012

Truvada gains FDA approval as HIV preventive

The daily pill is the first aimed at reducing the risk of contracting HIV in healthy people who are at high risk of contracting AIDS. It will have a boxed warning that it should be used only by people whose HIV-negative status is confirmed prior to prescription and at least every three months after.

18 Jul 2012

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

Though the FDA's Monday approval of the antiretroviral drug Truvada for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection among people at risk of contracting the virus "was hailed by many as an important step in the fight against AIDS, concerns that people will incorrectly use the drug -- potentially spurring drug resistance -- led others to blast the agency for not laying down tougher rules," the Wall Street Journal's "Health Blog" writes.

18 Jul 2012

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

The FDA on Monday announced the approval of the first drug for pre-exposure prophylaxis (PrEP) to prevent HIV among people at risk of contracting the virus, "which some are calling a landmark in the fight against AIDS," ABC News reports.

18 Jul 2012

First Edition: July 17, 2012

Today's headlines include a report that concludes that few Americans will pay more as a result of the health law.

17 Jul 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truto reduce the risk of sexually-acquired HIV infection in adults at high risk.

17 Jul 2012

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine and tenofovir disoproxil fumarate), in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.

17 Jul 2012

Studies show success, highlight challenges of PrEP strategy

The results of three clinical trials published on Wednesday in the New England Journal of Medicine show that the antiretroviral drug Truvada, a combination of tenofovir and emtracitabine, can be "highly effective at preventing infection in HIV-free individuals -- as long as those individuals take the drug every day as prescribed," CNN's "The Chart" reports (7/11).

13 Jul 2012

Truvada News and Research

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

GlobalPost examines debate surrounding PrEP

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Merck signs two licensing agreements for investigational HIV drug candidates

Dapivirine Phase III trial now underway in Africa to treat HIV in women

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

Views on AIDS: Despite advances, still no cure, no vaccine, and indifference grows

South Africa making progress against HIV/AIDS, but still more effort needed, health minister says

UNMC's ART injectables can successfully treat HIV infection

NPR reports on Brazilian clinical trial of Truvada as prevention strategy

Clinical trial to evaluate maraviroc-based PrEP regimens for HIV prevention

Truvada gains FDA approval as HIV preventive

Advocates, policy experts respond to FDA approval of Truvada for HIV prevention

FDA approves Truvada as HIV prevention strategy for high-risk, uninfected individuals

First Edition: July 17, 2012

U.S. FDA approves Gilead’s Truvada to minimize risk of sexually-acquired HIV infection

Gilead receives FDA approval for Truvada to reduce risk of sexually acquired HIV-1 infection

Studies show success, highlight challenges of PrEP strategy

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News